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Results: Progressive histopathologic changes characteristic of devel-
oping OA were observed concomitantly with aging. This change was
initiated by the disruption of the weight-bearing regions of articular
cartilage at 6 months of age, and subsequent changes such as cloning
of chondrocytes or loss of Safranin-O staining were recognized from
8 months of age onward. The ﬁgure shows the Mankin scores obtained
from sections stained with Safranin-O. As shown in this ﬁgure, the scores
were increased with aging in both groups. Statistical signiﬁcance was
recognized between two groups only in the early phase at 6 months
(p = 0.032). This data was consistent with the data of gross appearance.
Conclusions: The present study demonstrated that menaquinones could
delay the progression of osteoarthritis. To our knowledge, this is the ﬁrst
report to discuss the effect of menaquinones on the pathological feature
of OA.
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Purpose: To evaluate the efﬁcacy and tolerability of one single hyaluronic
acid (Adant®) intra articular (IA) injection for hip osteoarthritis (OA).
Methods: A randomised, double-blind (investigator blinded to the proce-
dure), placebo-controlled trial. Patients (age over 30) with symptomatic
hip OA (pain level on VAS >40mm), Kellgren Lawrence grade II or III, were
randomly allocated to receive one ﬂuoroscopically guided IA injection of
hyaluronic acid (2.5ml) or placebo (2.5ml). Patients were followed up
every month for 3 months. The mean outcome measure was the level
of pain recorded on a VAS (0–100mm) at month 3 and compared with
baseline. Secondary outcomes included the percentage of responders
according to the OMERACT-OARSI criteria, the Western Ontario and
McMaster Universities (WOMAC) OA index subscores on pain, stiffness
and disability, the patient’s and physician’s global assessments. Safety
was assessed at each visit. Statistical analysis was performed on the
inter-group difference in the intent-to-treat population (ITT) and in the per
protocol (PP) population. Missing data were replaced by carrying forward
the last outcome.
Results: Eighty-ﬁve patients were included, and were randomized in the
hyaluronic acid group (n = 42) or in the placebo group (n = 43). Baseline
characteristics were similar between the two groups. The number of drops
out was 5% (n=4). At end point, the decrease in pain was −7.8 (24.95)
and −9.12 (27.37) in the hyaluronic acid and placebo groups respectively,
in the ITT population (p = 0.98). Same result was found in PP analysis.
The OMERACT-OARSI responder rate was 33.3% in the hyaluronic acid
group and 32.5% in the placebo group (p = 0.94). There was no signiﬁcant
difference, both in ITT and in PP analysis, in secondary end points as well
as in the consumption of rescue medication between placebo and verum.
There was no difference in the frequency of adverse events between
groups.
Conclusions: This study failed to show a superior symptomatic effect
of a single IA hyaluronic acid injection (Adant®) over placebo in patients
with hip OA. Further studies are required to explore the potential efﬁcacy
of more than one single intra articular injection in hip OA.
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Purpose: Elucidate if a daily common clinical administration of two
intraarticular drugs as Hyaluronic Acid (H.A.) used to treat osteoarthrosis
and Bupivacaine used as local anaesthesia, cause increase degradation
of Hyaluronic Acid.
Methods: In vitro studies with ﬁve commercial H.A. have been used for
this study, (Synvisc®, Coxarthrum®, Go-on®, Hyalgan® and Durolane®)
with Bupivacaine at three different concentrations (0.25%, 0.50% and
0.75%) with/without adrenaline (1/200,000), with 24 hours incubation at
4ºC and 37ºC. Cromatography procedures (molecular exclusion HPLC)
have been used for determination of molecular weight and degradation
percentage of H.A. Anova-Manova and Kendall’s correlation have been
used to determinate statistiscal signiﬁcance.
Results: Synvisc® and Durolane® have shown less degradation and
different behavior than Coxarthrum®, Hyalgan® and Go-on® (Kendall’s
correlation p< 0.05). Temperature of incubation modiﬁed the degradation
of H.A. Durolane® and Synvisc® at 4ºC showed higher degradation
than at 37ºC (p< 0.05), otherwise happens for Coxarthrum®, Go-on®
and Hyalgan® that increased degradation at 37ºC (p< 0.05). Higher
concentration of Bupivacaine increased the degradation of H.A. in all
cases (p< 0.05) and the concomitant use of adrenaline increased the
degradation in the three concentrations used at the present study for
Synvisc®, 0.25 and 0.75 for Coxarthrum®, only at 0.75 for Durolane® and
0.25 for Go-on® (p< 0.05). Adrenaline seems not to increase degradation
over Hyalgan.
Conclusions: Bupivacaine administration (with/without adrenaline) with
H.A. must be valued before concomitant intraarticular administration
because Bupivacaine increased H.A degradation of all the H.A. studied.
Durolane® and Synvisc® have shown less degradation (6 to 20%) and
different behavior than Coxarthrum®, Hyalgan®, Go-on® (12 to 20%, 27
to 29% and 28 to 39% respectively). Higher concentration of Bupivacaine
and the concomitant use of adrenaline increased the degradation of H.A.
in all cases except the concomitant use of adrenaline that seems not to
affect Durolane® degradation except at highest Bupivacaine concentra-
tion.
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Purpose: Chondroitin sulfate (CS) is a SYSADOA eliciting an anti-
inﬂammatory effect. Since patients take CS over long periods, it was
of interest to assess whether CS modulates the activity of cytochrome
P450 isoforms (P450).
Methods: Two models were used, chronic intake of CS in control rabbits
and in rabbits with a down-regulated P450 by an inﬂammatory reaction
(IR). Six groups of 5 rabbits were used; three were used to assess the
effect of CS on P450, one without CS and two receiving orally around
20mg/kg/day CS for 20 and 30 days; three groups received turpentine
s.c. generating an aseptic IR (AIR) 48 h before their sacriﬁce, e.g. days
−2, 18 and 28, exposed to CS for 0, 20 or 30 days, respectively. CYP3A6,
CYP1A2 and NADPH P450 reductase (NADPH) activity, expression and
RNAm were assessed in the hepatocytes.
Results: Compared with control rabbits, 20 and 30 days CS did not affect
the activity of CYP3A6, e.g. 15582±1330, 13480±3052 and 14701±841,
and of CYP1A2, e.g. 6532±1203, 11612±2403 and 7494±746, arbitrary
Poster Presentations – Therapy – Pharmacologic S227
units. The AIR increased seromucoids to 95.1±5.7 vs 8.4±1.6mg/dl
in controls (p< 0.05). The AIR reduced CYP3A6 activity to 5972±464,
5415±541 and 2639±747, and CYP1A2 activity, 3026±113, 3856±1151,
3805±753 for control, 20 and 30 days of CS, respectively (p< 0.05
compared without AIR). CS did not affect NADPH activity or expression.
Conclusions: It is concluded that CS does not affect activity or expres-
sion of CYP3A6 and CYP1A2, nor prevents AIR-induced down-regulation.
These results are in agreement with the absence of CS-drug interactions
in humans.
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Purpose: To investigate the six-month efﬁcacy of a three intra-articular
hyaluronic acid (HA) injection course on pain relief in osteoarthritis (OA)
of the carpometacarpal joint (CMC).
Methods: Thirty-nine female patients affected by symptomatic CMC OA
(aged 66±8 years, mean±SD) were treated with three once-weekly intra-
articular injections of HA (Hyalgan 1ml). All subjects met ACR criteria
for hand OA and had CMC OA grade 1−4 according to Kellgren and
Lawrence on standard X-ray performed within 6 months before the
inclusion. Fifty-nine CMC joints were treated and evaluated (twenty-three
patients underwent to bilateral injections, thirteen patients had only one
hand treated). Patients were followed for a 6-month period after the last
injection. Treatment efﬁcacy was assessed through visual analogue scale
(VAS) pain quantiﬁcation (baseline; 2nd and 3rd injection; one, three and
six months after the last injection). Side effects were recorded.
Results: VAS was signiﬁcantly reduced after the ﬁrst injection (2nd
injection vs baseline, p< 0.01; 3rd injection vs baseline, p< 0.0001;
3rd injection vs 2nd injection, p< 0.05) and reached the slowest score
one month after the last injection. The efﬁcacy was maintained for all
the 6-month follow-up period (one month vs baseline, p< 0.0001;three
months vs baseline, p< 0.0001; six months vs baseline, p = 0.0001 – one
month vs 3rd injection, p = n.s.;three months vs 3rd injection, p = n.s.; six
months vs 3rd injection, p = n.s.). Only minor side effects were observed
(mild pain and/or ecchymosis in injection site).
Conclusions: Our study supports viscosupplementation with HA as a
safe and efﬁcacious approach for symptomatic CMC OA. Our schedule
based on three weekly intra-articular injections supplies pain relief lasting
as long as 6 months with negligible side-effects.
Further studies are needed to determine the long-term efﬁcacy and the
optimal treatment schedule.
535 TWELVE WEEKS MULTIMODAL CONSERVATIVE TREATMENT
OF KNEE OSTEOARTHRITIS USING A NEWLY DEVELOPED
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Purpose: Recently extensive evidence based recommendations have
been made in the Netherlands for diagnosis and treatment of knee and hip
osteoarthritis (OA). Based on this a three months standardized treatment
protocol was developed including education, advice about weight loss
and lifestyle measures, use of analgetics, referral for physical therapy
and when necessary other interventions like intra-articular injections. To
implement this protocol an outpatient clinic was initiated for conservative
treatment of primary osteoarthritis of the knee. The aim of this study was
to assess the results of a standardized conservative treatment protocol
for knee OA.
Methods: Patients with symptomatic clinical knee OA according to the
ACR classiﬁcation criteria referred to the rheumatology department by
general practitioners were treated at the outpatient clinic of the Sint
Maartenskliniek. In addition to patient education, treatment consisted of
three main modalities: stepwise analgesia, referral to exercise therapy
using ‘graded activity principle’ and weight reduction advises if necessary.
Visits took place at the outpatient clinic at intake and after 12 weeks;
patients were contacted by telephone at 4 and 8 weeks. Pain and ADL
function were measured using a Likert scale (0−10) for pain and patient
global assessment (PGA) and using WOMAC compatible subscales of
the Knee injury and Osteoarthritis Outcome Score (WKOOS) (Likert
scale version). WKOOS based OMERACT-OARSI responder criteria were
measured in all patients after twelve weeks. Finally kinesiophobia was
measured using the Tampa Scale of Kinesiophobia (TSK).
Results: Fifteen patients (13 females, mean age (±SD) 62±12) were
thus far included. At intake the following values were found (mean±SD):
pain and PGA 6.1±1.9 and 6.1±2.5 respectively, WOMAC compatible
subscales for pain, stiffness and function 11±4.4, 4.5±1.5 and 38±14
respectively, BMI 34.4±4.8 and TSK scores 40±6 (cut-off for irrational
kinesiophobia >37). After twelve weeks pain, PGA, BMI and TSK did
not change signiﬁcantly: scores were 6.4±3.2 (p = 0.8), 6.2±2.7 (p = 0.9),
33.7±5.0 (p = 0.09) and 39±5 (p = 0.3) respectively. WKOOS based
OMERACT-OARSI responder criteria were however met in 40% of the
patients.
Conclusions: Although 40% of patients met the OMERACT-OARSI re-
sponder criteria using this protocol, mean pain and ADL function did not
change, indicating that a subgroup of patient worsened. However, this
sample probably reﬂects a highly selected population. Future research
should be directed at identifying prognostic factors for non-response such
as body weight and kinesiophobia.
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Purpose: Joint immobilization is an essential treatment in daily exami-
nations but it also causes degeneration of the articular cartilage. Intra-
articular hyaluronan (HA) injection is widely used as a treatment of
osteoarthritis (OA) due to its physical and biological activities. Though
a large number of studies regarding chondroprotective effects of HA on
OA animal models have been reported, most of these are based on joint
instability models by resection of ligaments or meniscus. There were few
reports of the effects of HA regarding immobilized joints. In this study, we
examined the chondroprotective effects of exogenously administered HA
in a rat immobilized knee model.
Methods: Animals: A total of 84 adult male Sprague-Dawley rats weigh-
ing from 380–400 g were used. Their unilateral knee joints were immo-
bilized rigidly at 150º in ﬂexion with a plastic plate and metal screws
placed internal but extra-articularly for various periods (1, 2, 4, 6, 8,
12, and 16 weeks). 50 ml of HA (molecular weight = 1.9×106) was
administered intra-articularly for HA group on the day after surgery
and once a week until euthanasia. The same amount of saline was
administered for control group. Tissue Preparation: The specimens were
ﬁxed with 4% paraformaldehyde. After decalciﬁcation and dehydration,
the specimens were embedded in parafﬁn. The embedded tissue was
cut into 5mm sagittal sections. Standardized serial sections were created
in the medial midcondylar region of the knee. Histological Evaluation:
We chose 3 areas (non-contact, transitional, and contact area) from the
articular surface of the femur and tibia. A degree of degeneration in each
section from the 6 areas was evaluated respectively using the histological
grading scheme (modiﬁed Mankin’s score). The thickness of the total
articular cartilage was measured and the number of chondrocytes was
counted in each area, respectively.
Figure 1. Femur contact area 16 weeks.
